logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. drugs

    FiltersReset Filters
    3 results

    • eribulin mesylate

      (Eribulin Mesylate)
      Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      Usage: Eribulin mesylate injection is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapeutic regimens, including an anthracycline and a taxane. It is also used for unresectable or metastatic liposarcoma in those who have received a prior anthracycline-containing regimen.

    • fosaprepitant

      (FOSAPREPITANT DIMEGLUMINE)
      Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      Usage: Fosaprepitant for injection is indicated for preventing acute and delayed nausea and vomiting in adults and pediatric patients (6 months and older) undergoing highly or moderately emetogenic cancer chemotherapy. It is not studied for treating established nausea and vomiting.

    • fulvestrant

      (fulvestrant)
      Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      Usage: Fulvestrant injection is indicated for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women, either as monotherapy for those not previously treated with endocrine therapy or as part of combination therapy with ribociclib, palbociclib, or abemaciclib after disease progression.